Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-14
Based on 460 first isolates · GER · Febrile UTI / pyelonephritis · 2024-12-15 → 2025-12-14
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 80 % (76 %–83 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (11 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli not for this site
84 %
93 %
n = 29
meropenem MEM
trend · Escherichia coli reserve
83 %
83 %
n = 29
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
79 %
n = 29
mecillinam MEC
trend · Escherichia coli not for this site
77 %
79 %
n = 29
ceftriaxone CRO
trend · Escherichia coli
76 %
72 %
n = 29
ciprofloxacin CIP
trend · Escherichia coli
75 %
83 %
n = 29
72 %
72 %
n = 29
trimethoprim TMP
trend · Escherichia coli not for this site
68 %
72 %
n = 29
52 %
52 %
n = 29
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
17 %
n = 29
4 %
3 %
n = 29
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
7 %
n = 29

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
4 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.